Targeting In-Stent-Stenosis with RGD- and CXCL1-Coated Mini-Stents in Mice

Sakine Simsekylmaz1,2,3*, Elisa A. Liehn1,4,5*, Stefan Weinandy2,6, Fabian Schreiber7, Remco T. A. Megens8, Wendy Theelen1, Ralf Smeets9, Stefan Jockenhövel6, Thomas Gries7, Martin Möller2, Doris Klee2, Christian Weber8‡, Alma Zernecke10‡*

1 Institute for Molecular Cardiovascular Research, University Hospital Aachen, RWTH Aachen University, Aachen, Germany, 2 Institute of Technical and Macromolecular Chemistry, RWTH Aachen University, Aachen, Germany, 3 Biochemistry Institute, Justus-Liebig-University, Giessen, Germany, 4 Human Genetic Laboratory, University of Medicine and Pharmacy, Craiova, Romania, 5 IZKF Aachen, University Hospital Aachen, RWTH Aachen University, Aachen, Germany, 6 Department of Applied Medical Engineering, Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, Aachen, Germany, 7 Institute for Textile Technology, RWTH Aachen University, Aachen, Germany, 8 Institute for Cardiovascular Prevention, Ludwig-Maximilians University Munich, Munich, Germany, 9 Department of Oral and Maxillofacial Surgery, Center of Clinical Neurosciences, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, 10 Institute for Experimental Biomedicine, University Hospital Würzburg, Würzburg, Germany

* These authors contributed equally to this work.
‡ These authors also contributed equally to this work.
* alma.zernecke@uni-wuerzburg.de

Abstract

Atherosclerotic lesions that critically narrow the artery can necessitate an angioplasty and stent implantation. Long-term therapeutic effects, however, are limited by excessive arterial remodeling. We here employed a miniaturized nitinol-stent coated with star-shaped polyethylene glycol (star-PEG), and evaluated its bio-functionalization with RGD and CXCL1 for improving in-stent stenosis after implantation into carotid arteries of mice. Nitinol foils or stents (bare metal) were coated with star-PEG, and bio-functionalized with RGD, or RGD/CXCL1. Cell adhesion to star-PEG-coated nitinol foils was unaltered or reduced, whereas bio-functionalization with RGD but foremost RGD/CXCL1 increased adhesion of early angiogenic outgrowth cells (EOCs) and endothelial cells but not smooth muscle cells when compared with bare metal foils. Stimulation of cells with RGD/CXCL1 furthermore increased the proliferation of EOCs. In vivo, bio-functionalization with RGD/CXCL1 significantly reduced neointima formation and thrombus formation, and increased re-endothelialization in apoE−/− carotid arteries compared with bare-metal nitinol stents, star-PEG-coated stents, and stents bio-functionalized with RGD only. Bio-functionalization of star-PEG-coated nitinol-stents with RGD/CXCL1 reduced in-stent neointima formation. By supporting the adhesion and proliferation of endothelial progenitor cells, RGD/CXCL1 coating of stents may help to accelerate endothelial repair after stent implantation, and thus may harbor the potential to limit the complication of in-stent restenosis in clinical approaches.
Introduction

Cardiovascular disease is the most frequent cause of death in industrialized nations. Atherosclerosis as the underlying disease [1,2] can result in a narrowing of the artery, necessitating angioplasty and stent-implantation. Long-term effects of such therapy, however, are limited by arterial remodeling and restenosis, and the risk of life-threatening stent-thrombosis [3,4]. While meta-analyses have shown no differences in stent thrombosis comparing drug-eluting with bare-metal stents [5–7], there is also evidence of an increased risk of very late stent thrombosis with drug-eluting stents [6,8–10], possibly related to reduced vessel wall re-endothelialization [11–13].

Different factors contribute to endothelial repair and plaque formation. The chemokine CXCL1 enhances re-endothelialization and reduces neointima formation, and its receptor CXCR2 mediates homing of circulating endothelial progenitor cells to sites of arterial injury in mice [14–16]. Furthermore, stents coated with cRGD (Arg-Gly-Asp)-peptide, which preferentially bind \( \alpha_\text{v}\beta_3 \) and \( \alpha_\text{v}\beta_5 \)-integrins, attract endothelial progenitor cells to stented areas, accelerating wound healing in swine [17].

Thus, RGD and CXCL1 may serve as candidates for the coating of stents to enhance re-endothelialization after implantation. We here employed a miniaturized stent implanted into the carotid artery of mice [18], and evaluated its bio-functionalization. Indeed, we could show that the bio-functionalization of star-PEG-coated nitinol-stents with RGD/CXCL1 supported the adhesion and proliferation of endothelial progenitor cells and thereby reduced in-stent neointima formation.

Materials and Methods

Cell culture

Isolation and cell culture of early angiogenic outgrowth cells (EOCs) were performed as described [14,19–22]. Briefly, peripheral blood mononuclear cells were separated by Biocoll density gradient centrifugation (Biochrom) from buffy coats derived from healthy human donors and plated on fibronectin-coated (10\( \mu \)g/ml) 6-well plates (1x10^7 cells/well) in endothelial growth medium MV2 (PromoCell), changed at day 1 and 4, and harvested at day 7. Under these conditions, cultured cells developed a spindle-shaped appearance, formed typical cell clusters and bound endothelial-specific lectin, identifying these as early angiogenic outgrowth cells. Human umbilical vein endothelial cells (HUVECs, PromoCell, Cat. No. C-12200) were cultured in endothelial cell growth medium and used between passages 3 to 6. Human coronary artery smooth muscle cells (SMCs, PromoCell, Cat. No. C-12511) were cultured in smooth muscle cell growth medium 2 (PromoCell) and used between passages 3 to 6. Adherent cells were detached for experiments by applying accutase (PAA Laboratories) for 5 minutes at 37°C.

Stent braiding- and nitinol-coating

Stents or nitinol foils were processed as previously described [18]. Stents were manually braided using 16 nitinol wires (50\( \mu \)m diameter) yielding an outer dimension of 500\( \mu \)m, and heated in a high-temperature oven for shape settings. Stents or nitinol foils were cleaned by sonication in acetone, water, and 2-propanol followed by drying in a nitrogen stream. Surface activation was achieved by treatment with UV/ozone before use for aminofunctionalization. Substrates were immersed in a solution of N-[3-(trimethoxysilyl)-propyl]ethylenediamine in dry toluene, and the desired amount of isocyanate end group terminated six-arm star-shaped copolymer of 80% ethylene oxide and 20% propylene oxide NCO-sP(EO-stat-PO)
(Mn = 12,000g/mol; PD = 1.15) was dissolved in dry tetrahydrofurane under an inert gas atmosphere. Thereafter, the solution was filtered through 0.2 μm syringe filters and used for hydrogel coating (5 min) of stents or foils. Subsequently, biofunctionalization was achieved by overnight incubation in 300μl polymer solution containing 50μg/ml RGD or 50μg/ml RGD and 1μg/ml CXCL1 in PBS, followed by extensive washing in water.

Adhesion assay under static conditions
For adhesion assays under static conditions, 1x10⁵ cells were seeded on nitinol foils coated with star-PEG with/without RGD and/or CXCL1. After an overnight incubation and 2 washing steps with 1x Dulbecco’s PBS (PAA), adherent cells were detected by staining with DAPI and visualized with a Leica DM-RXE fluorescence microscope. Adherent cells were quantified in 15 recorded high power fields per sample using Diskus software.

Proliferation and viability assay
Proliferation assays were performed in untreated cells, or after stimulation with RGD or a combination of RGD together with CXCL1 using the BrdU Cell Proliferation Assay, HTS (Calbiochem), according to the manufacturers’ instructions using 1x10⁵ cells/well in 96-well plates. Viability was tested using the fluorescent CellTiter-Blue™ cell viability assay (Promega), according to the manufacturers’ instructions.

Stent implantation and Immunohistochemistry
Stents were implanted into left carotid arteries of anesthetized (100 mg/kg ketamine hydrochloride and 10 mg/kg xylazine intraperitoneally) mice by inserting 500 μm silicon tubes containing the stent through an incision in the external carotid artery, and careful forward-feeding of the stent whilst retraction of the tube allowing for shape memory-based expansion [18]. In total, 38 mice underwent stent implantation but 6 mice died during the procedure and therefore were not considered for further analyses. All other 32 mice showed normal physiological behavior after the procedure and did not require any special treatment during the experiment. The following treatment groups were analyzed: n = 4 apolipoprotein E-deficient (apoE−/−) mice were implanted with bare metal nitinol-stents, n = 5 apoE−/− mice were implanted with nitinol-stents coated with star-PEG, n = 9 apoE−/− mice were implanted with star-PEG-coated stents bio-functionalized with RGD and n = 8 apoE−/− mice were implanted with star-PEG-coated stents bio-functionalized with RGD/CXCL1. All apoE−/− mice were placed on a high-fat diet containing 21% fat and 0.15% cholesterol (Altromin) after the procedure. C57Bl/6 control mice (n = 6) were implanted with bare metal nitinol-stents and fed a normal chow-diet fed (Ssniff). Mice were sacrificed one week after stent placement under anesthesia (100 mg/kg ketamine hydrochloride and 10 mg/kg xylazine intraperitoneally) by intracardiac puncture and exsanguination, and the carotid arteries were fixed in situ with 4% paraformaldehyde. All experiments were conducted in accordance with the guidelines for the care and use of laboratory animals and approved by the Landesamt für Natur, Umwelt- und Verbraucherschutz Nordrhein-Westfalen (permit number 82–02.04.2011.A333) and complied with the German animal protection law. All surgeries were performed under ketamine/xylazine anesthesia and all efforts were made to minimize suffering. Carotid arteries were subsequently embedded in Technovit 9100NEU (Heraeus Kulzer). Serial sections (50μm; 3–5 per mouse) were generated within 500μm from the bifurcation using a cutting-grinding system technique (Exakt 400CS) with a diamond-band saw (Exakt 300) and quantified by Giemsa staining and planimetry of the area within elastic laminae and of the lumen (Diskus software, Hilgers); organized thrombi were detectable by black staining of fibrin depositions inside the neointima. Re-
endothelialization of luminal surface was detected after deplasting sections with xylene, 2-methoxyethylacrylate (MEA) and acetone and staining for endothelial cells using vWF mAb (clone A0082, DAKO) and secondary Cy3-conjugated Ab (Sigma Aldrich). Isotype controls (appropriate IgGs) and right carotid arteries served as controls. Images were recorded using a Leica DM-RXE fluorescence microscope and quantified with Diskus software.

Statistical analysis

Data are expressed as mean±SEM. Statistical calculations were performed using GraphPad Prism 6 (GraphPad Software Inc.). Data were tested for normality (D’Agostino and Pearson omnibus normality test) prior to analysis and non-parametric statistics as applicable. One-way ANOVA analysis followed by the Tukey’s multiple comparison test or, if non-parametric, Kruskal-Wallis test followed by the Dunn’s post-test were applied as appropriate and indicated. *P-values <0.05 were considered statistically significant.

Results

The effects of RGD and CXCL1 on cell adhesion were evaluated when employed as specific surface coatings in vitro. EOCs, HUVECs and SMCs were seeded on bare metal nitinol-foils with/without coating with star-PEG, bio-functionalized with RGD, or RGD in combination with CXCL1. A significant increase in EOC and HUVEC adhesion to RGD but foremost RGD/CXCL1-biofunctionalized foils was revealed compared to bare-metal controls or star-PEG-coated foils (Fig 1A). In contrast, SMC adhesion was not altered by RGD/CXCL1 bio-functionalization,
and even blocked by star-PEG coating alone (Fig 1A). Stimulation of cells with RGD/CXCL1 significantly augmented the proliferation of EOCs but not HUVECs, whereas proliferation of SMCs was even inhibited compared to untreated cells (Fig 1B). None of these treatments impaired cell viability of HUVECs and SMCs (Fig 2). These data indicate that the combination of RGD/CXCL1 provides support for EOC adhesion and proliferation, and the attachment of HUVECs and SMCs, but not their proliferation.

To scrutinize effects of these coatings in vivo, in-stent intima formation was assessed in carotid arteries of apoE−/− mice one week after stent placement as a model of in-stent stenosis in hyperlipidemic subjects. In contrast to drug-eluting stents for human application, where the kinetics of drug-delivery are of crucial importance, stents used in our study were coated with a polymer, to which RGD and/or CXCL1 were covalently linked, ensuring a densely packed polymer network to produce a RGD and/or CXCL1-coated surface, which keeps its nonfouling properties for at least 7 days [23] and up to 4 weeks at 37°C [24]. We confirmed the stability of the stent coatings after 7-days of washing in PBS under agitation at 37°C by incubation with RITC-conjugated BSA, and could detect an overall unspecific protein binding on only aminofunctionalized stents, whereas no signal could be detected on star-PEG coated stents (data no shown).

Compared to C57Bl/6 mice on normal chow diet, the significant increase in in-stent stenosis, evidenced in high-fat diet fed apoE−/− mice implanted with bare-metal nitinol-stents, star-PEG-coated stents, or stents bio-functionalized with RGD, could be reduced by bio-functionalization with RGD/CXCL1 (Fig 3A and 3B). Thrombus formation was increased in arteries implanted with star-PEG-coated stents, but reduced in RGD-bio-functionalized stents, and almost completely prevented by bio-functionalization with RGD/CXCL1 (Fig 3C). Conversely, re-endothelialization was significantly increased in RGD/CXCL1-bio-functionalized stents (Fig 3D).

These data indicate that bio-functionalizing of star-PEG-coated nitinol-stents with RGD/CXCL1 reduces intima formation after implantation in apoE−/− mice, associated with an enhanced re-endothelialization.

Discussion

Revascularizing interventions and stent-implantation lead to a mechanic injury of the endothelial cell lining, inducing thrombocyte aggregation at the injured artery. The administration of thrombocyte aggregation inhibitors is therefore mandatory, but associated with severe bleeding complications [3]. SMC proliferation predominates neointimal hyperplasia at later stages, and is targeted by the drug-eluting stents that inhibit cell proliferation. These therapies, however,
can also impair endothelial cell recovery [12], which can precipitate life-threatening late stent-thrombosis. Treatment approaches are therefore required to selectively enhance endothelial recovery after stent-implantation.

We here defined the use of stents coated with a combination of signaling molecules for specifically attracting cells for endothelial repair. We demonstrate that star-PEG bio-functionalization with RGD (n = 9) or RGD/CXCL1 (n = 8), (a) Representative Giemsa-stained sections (scale bars, 200μm) from apoE−/− mice. Quantification of in-stent intima formation (b) and thrombus formation (c). (d) Representative images of vWF-staining (red); cell nuclei were counterstained by DAPI (L, lumen; x, stent struts; scale bar, 50μm); quantification of re-endothelialization. *P<0.05. Kruskal-Wallis test with Dunn’s post-test.

doi:10.1371/journal.pone.0155829.g003

Taken together, our findings indicate that in-stent neo-intima formation can be reduced by bio-functionalizing star-PEG-coated stents with RGD and CXCL1, harboring the potential of limiting in-stent restenosis in clinical approaches.
Acknowledgments
We thank Angela Freund and Roya Soltan for excellent technical assistance.

Author Contributions
Conceived and designed the experiments: AZ CW SJ MM DK TG. Performed the experiments: SS EAL SW FS RTAM WT. Analyzed the data: SS EAL SW FS CW AZ. Contributed reagents/materials/analysis tools: EAL RS SJ CW AZ MM DK SJ. Wrote the paper: SS EAL SW FS RTAM RS DK CW AZ.

References
1. Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med. 2011; 17: 1410–1422. doi:10.1038/nm.2538 PMID: 22064431
2. Liehn EA, Cabrera-Fuentes HA. Inflammation between defense and disease: impact on tissue repair and chronic sickness. Discoveries. 2015; 3: e42.
3. Lenzen MJ, Boersma E, Bertrand ME, Maier W, Moris C, Piscione F, et al. Management and outcome of patients with established coronary artery disease: the Euro Heart Survey on coronary revascularization. Eur Heart J. 2005; 26: 1169–1179. PMID: 15802360
4. Simekylimaz S, Liehn EA, Militaru C, Vogt F. Progress in interventional cardiology: challenges for the future. Thromb Haemost. 2015; 113: 464–472. doi:10.1160/TH14-07-0599 PMID: 25608683
5. Bangalore S, Kumar S, Fusaro M, Amoroso N, Attubato MJ, Feit F, et al. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation. 2012; 125: 2873–2891. doi: 10.1161/CIRCULATIONAHA.112.097014 PMID: 22586281
6. De Luca G, Dirksen MT, Spaulding C, Kelbaek H, Schalij M, Thuesen L, et al. Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials. Arch Int Med. 2012; 172: 611–621.
7. Wang XZ, Xu K, Li Y, Jing QM, Liu HW, Zhao X, et al. Comparison of the efficacy of drug-eluting stents versus bare-metal stents for the treatment of left main coronary artery disease. Chin Med J (Engl). 2015; 128: 721–726.
8. Kalesan B, Pilgrim T, Heinimann K, Raber L, Stefanini GG, Valgimigli M, et al. Comparison of drug-eluting stents with bare metal stents in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2015; 33: 977–987.
9. Wallace EL, Abdel-Latif A, Charnigo R, Moliterno DJ, Brodie B, Matnani R, et al. Meta-analysis of long-term outcomes for drug-eluting stents versus bare-metal stents in primary percutaneous coronary interventions for ST-segment elevation myocardial infarction. Am J Cardiol. 2012; 109: 932–940. doi: 10.1016/j.amjcard.2011.11.021 PMID: 22221949
10. Sarno G, Lagerqvist B, Nilsson J, Frobert O, Hambraeus K, Varenhorst C, et al. Stent thrombosis in new-generation drug-eluting stents in patients with STEMI undergoing primary PCI: a report from SCAAR. J Am Coll Cardiol. 2014; 64: 16–24. doi: 10.1016/j.jacc.2014.04.022 PMID: 24998123
11. Sousa JE, Costa MA, Abizaid AC, Rensing BJ, Abizaid AS, Tanajura LF, et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation. 2001; 104: 2007–2011. PMID:11673337
12. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006; 48: 193–202. PMID: 16814667
13. Nakazato K, Mizukami H, Ohtake H, Sakamoto N, Yamaki T, Yamaguchi O, et al. Stenting Strategy and Follow-up Results of Multi-Center Registry in Fukushima City for Left Main Coronary Artery Disease: Bare Metal Stent Versus Drug-Eluting Stent. Fukushima J Med Sci. 2015; 61: 79–85. doi:10.5387/fms.2015-5 PMID: 26135665
14. Hristov M, Zemecke A, Bidzhekov K, Liehn EA, Shagdarsuren E, Ludwig A, et al. Importance of CXC chemokine receptor 2 in the homing of human peripheral blood endothelial progenitor cells to sites of arterial injury. Circ Res. 2007; 100: 590–597. PMID: 17272612
15. Kubo N, McCurdy S, Boisvert WA. Defective Fas Expression on Bone Marrow Derived Cells Alters Atherosclerotic Plaque Morphology in Hyperlipidemic Mice. Discoveries. 2015; 3(1): e37. PMID: 26322329
16. Liehn EA, Schober A, Weber C. Blockade of keratinocyte-derived chemokine inhibits endothelial recovery and enhances plaque formation after arterial injury in ApoE-deficient mice. Arterioscler Thromb Vasc Biol. 2004; 24: 1891–1896. PMID: 15331432

17. Blindt R, Vogt F, Astafieva I, Fach C, Hristov M, Krott N, et al. A novel drug-eluting stent coated with an integrin-binding cyclic Arg-Gly-Asp peptide inhibits neointimal hyperplasia by recruiting endothelial progenitor cells. J Am Coll Cardiol. 2006; 47: 1786–1795. PMID: 16682302

18. Soehnlein O, Wantha S, Simsek yilmaz S, Doring Y, Megens RT, Mause SF, et al. Neutrophil-derived cathelicidin protects from neointimal hyperplasia. Sci Transl Med. 2011; 3: 103ra198.

19. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997; 275: 964–967. PMID: 9020076

20. Kalka C, Masuda H, Takahashi T, Kalka-Moll WM, Silver M, Kearney M, et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci U S A. 2000; 97: 3422–3427. PMID: 10725398

21. Rehman J, Li J, Orschell CM, March KL. Peripheral blood *endothelial progenitor cells* are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation. 2003; 107: 1164–1169. PMID: 12615796

22. Treves AJ, Yagoda D, Haimovitz A, Ramu N, Rachmilewitz D, Fuks Z. The isolation and purification of human peripheral blood monocytes in cell suspension. J Immunol Methods. 1980; 39: 71–80. PMID: 7462647

23. Groll J, Ademovic Z, Ameringer T, Klee D, Moeller M. Comparison of coatings from reactive star shaped PEG-stat-PPG prepolymers and grafted linear PEG for biological and medical applications. Biomacromolecules. 2005; 6: 956–962. PMID: 15762665

24. Groll J, Fiedler J, Engelhard E, Ameringer T, Tuqulu S, Klok HA, et al. A novel star PEG-derived surface coating for specific cell adhesion. J Biomed Mater Res A. 2005; 74: 607–617. PMID: 16035061